−2.85USD
−151.76 MUSD
57.62 M
About Akero Therapeutics, Inc.
Sector
CEO
Andrew Cheng
Headquarters
South San Francisco
Website
Employees (FY)
56
Founded
2017
ISIN
US00973Y1082
FIGI
BBG00L9211Y8
Akero Therapeutics, Inc. is a clinical-stage company, which engages in the development of treatments for patients with serious metabolic diseases. The firm's lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21, or FGF21, which is an endogenously expressed hormone that protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company was founded by Jonathan Young and Timothy Rolph in January 2017 and is headquartered in South San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of AKRO is 20.51 USD — it has decreased by 5.05% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Akero Therapeutics, Inc. stocks are traded under the ticker AKRO.
Akero Therapeutics, Inc. is going to release the next earnings report on May 14, 2024. Keep track of upcoming events with our Earnings Calendar.
AKRO stock is 5.78% volatile and has beta coefficient of 2.42. Check out the list of the most volatile stocks — is Akero Therapeutics, Inc. there?
One year price forecast for Akero Therapeutics, Inc. has a max estimate of 60.00 USD and a min estimate of 42.00 USD.
AKRO earnings for the last quarter are −0.71 USD whereas the estimation was −0.70 USD which accounts for −0.89% surprise. Estimated earnings for the next quarter are −0.83 USD. See more details about Akero Therapeutics, Inc. earnings.
Yes, you can track Akero Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
AKRO stock has fallen by 7.40% compared to the previous week, the month change is a 23.18% fall, over the last year Akero Therapeutics, Inc. has showed a 49.45% decrease.
AKRO net income for the last quarter is −55.19 M USD, while the quarter before that showed −39.66 M USD of net income which accounts for −39.15% change. Track more Akero Therapeutics, Inc. financial stats to get the full picture.
Today Akero Therapeutics, Inc. has the market capitalization of 1.49 B, it has decreased by 1.07% over the last week.
No, AKRO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, AKRO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Akero Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 56.00 employees. See our rating of the largest employees — is Akero Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Akero Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Akero Therapeutics, Inc. stock shows the strong sell signal. See more of Akero Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Akero Therapeutics, Inc. future price: according to them, AKRO price has a max estimate of 60.00 USD and a min estimate of 42.00 USD. Read a more detailed Akero Therapeutics, Inc. forecast: see what analysts think of Akero Therapeutics, Inc. and suggest that you do with its stocks.